Cooley advised Iterum Therapeutics plc on its $80 million initial public offering of 6,150,000 ordinary shares. The underwriters have a 30-day option to purchase up to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
